HiCM-188 therapy is named as a drug or biological intervention in 2 clinical trials in our China trial register, 1 of which is recruiting. The lead sponsor is HELP Therapeutics Co., Ltd.. Registered phases: Phase 3 and Phase 1/2. Conditions studied include Heart Failure.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07496372 | A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV) (ClinicalTrials.gov ↗) Heart Failure |
Phase 3 | Recruiting |
| NCT06340048 | Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure (ClinicalTrials.gov ↗) Heart Failure |
Phase 1/2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Heart Failure | 2 |
| Lead sponsor | Trials |
|---|---|
| HELP Therapeutics Co., Ltd. | 2 |
| Register | HiCM-188 therapy trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how HiCM-188 therapy works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists HiCM-188 therapy (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.